Letrozole or Femara is indicated for breast cancer in post menopausal women.
Letrozole or Femara blocks an enzyme known as aromatase which in turn blocks the production of estrogen in peripheral tissues such as the fat cells.
Letrozole or Femara has the potential to affect the hormonal balance in the body and thus can cause weight gain, vaginal bleeding, and blood clots. However, these side effects do not occur as often as with other treatments for breast cancer such as tamoxifen.
People with existing hormonal or gynecological problems may not be suitable candidates to use Letrozole or Femara.
Letrozole or Femara affects hormonal levels and any drug that also affects hormonal levels can complicate the therapy.
J Clin Oncol 1996;12;2000
The relevant product monographs must be regarded as the appropriate sources of prescribing information.